Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
FDA Investigating Sarepta's Elevidys® after Second Patient Dies.
Journal: Human gene therapy
Published: August 05, 2025
Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives.
Journal: Biomedicines
Published: June 10, 2025
Givinostat (Duvyzat) for Duchenne muscular dystrophy.
Journal: The Medical letter on drugs and therapeutics
Published: January 06, 2025
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Journal: Expert opinion on drug safety
Published: December 25, 2024
The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.
Journal: Expert opinion on biological therapy
Published: August 17, 2024
In brief: Expanded indication for Elevidys.
Journal: The Medical letter on drugs and therapeutics
Published: August 13, 2024
Duchenne muscular dystrophy: promising early-stage clinical trials to watch.
Journal: Expert opinion on investigational drugs
Published: January 30, 2024
Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.
Journal: The Medical letter on drugs and therapeutics
Published: September 27, 2023
Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy.
Journal: Molecular therapy. Methods & clinical development
Published: March 04, 2023
Showing 1-11 of 11
Last Updated: 10/31/2025